Tobramycin Injection Hospira
 Tobramycin Ophthalmic Solution

drug-information.ru

|Tobramycin Injection Hospira Tobramycin Ophthalmic Solution

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Tobramycin

Dosage Form: Injection hospira

For intravenous infusion only after dilution.

ADD-Vantage® Vial

Rx only

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin and other antibacterial drugs, Tobramycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

WARNINGS

Patients treated with Tobramycin Injection and other aminoglycosides should be under close clinical observation, because these drugs have an inherent potential for causing ototoxicity and nephrotoxicity.

Neurotoxicity, manifested as both auditory and vestibular ototoxicity, can occur. The auditory changes are irreversible, are usually bilateral, and may be partial or total. Eighth-nerve impairment and nephrotoxicity may develop, primarily in patients having pre-existing renal damage and in those with normal renal function to whom aminoglycosides are administered for longer periods or in higher doses than those recommended. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions. The risk of aminoglycoside-induced hearing loss increases with the degree of exposure to either high peak or high trough serum concentrations. Patients who develop cochlear damage may not have symptoms during therapy to warn them of eighth-nerve toxicity, and partial or total irreversible bilateral deafness may continue to develop after the drug has been discontinued. Rarely, nephrotoxicity may not become apparent until the first few days after cessation of therapy. Aminoglycoside-induced nephrotoxicity usually is reversible.

Renal and eighth-nerve function should be closely monitored in patients with known or suspected renal impairment and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Peak and trough serum concentrations of aminoglycosides should be monitored periodically during therapy to assure adequate levels and to avoid potentially toxic levels. Prolonged serum concentrations above 12 mcg/mL should be avoided. Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation. Such accumulation, excessive peak concentrations, advanced age, and cumulative dose may contribute to ototoxicity and nephrotoxicity (see PRECAUTIONS). Urine should be examined for decreased specific gravity and increased excretion of protein, cells, and casts. Blood urea nitrogen, serum creatinine, and creatinine clearance should be measured periodically. When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of impairment of renal, vestibular, or auditory function requires discontinuation of the drug or dosage adjustment.

Tobramycin should be used with caution in premature and neonatal infants because of their renal immaturity and the resulting prolongation of serum half-life of the drug.

Concurrent and sequential use of other neurotoxic and/or nephrotoxic antibiotics, particularly other aminoglycosides (e.g., amikacin, streptomycin, neomycin, kanamycin, gentamicin, and paromomycin), cephaloridine, viomycin, polymyxin B, colistin, cisplatin, and vancomycin, should be avoided. Other factors that may increase patient risk are advanced age and dehydration.

Aminoglycosides should not be given concurrently with potent diuretics, such as ethacrynic acid and furosemide. Some diuretics themselves cause ototoxicity, and intravenously administered diuretics enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.

Aminoglycosides can cause fetal harm when administered to a pregnant woman (see PRECAUTIONS).

Tobramycin Description

Tobramycin sulfate, a water-soluble antibiotic of the aminoglycoside group, is derived from the actinomycete Streptomyces tenebrarius. Tobramycin Injection, USP is a clear and colorless sterile aqueous solution for parenteral administration.

Each mL contains Tobramycin sulfate equivalent to 10 mg Tobramycin; sodium metabisulfite added as an antioxidant, 1.5 mg; and edetate disodium added as a stabilizer, 0.1 mg. Contains sulfuric acid and may contain sodium hydroxide for pH adjustment. pH 4.5 (3.0 to 6.5).

Tobramycin sulfate is O - 3 - amino - 3 - deoxy - α - D - glucopyranosyl - (1→4) - O - [2,6 - diamino - 2,3,6 - trideoxy - α - D - ribo - hexopyranosyl - (1→6)] - 2 - deoxy - ,L - streptamine sulfate (2:5)(salt) and has the chemical formula (C18H37N5O9)2• 5H2SO4. The molecular weight is 1,425.45. The structural formula for Tobramycin is as follows:

Tobramycin - Clinical Pharmacology

Tobramycin is rapidly absorbed following intramuscular administration. Peak serum concentrations of Tobramycin occur between 30 and 90 minutes after intramuscular administration.

Following an intramuscular dose of 1 mg/kg of body weight, maximum serum concentrations reach about 4 mcg/mL, and measurable levels persist for as long as 8 hours. Therapeutic serum levels are generally considered to range from 4 to 6 mcg/mL. When Tobramycin is administered by intravenous infusion over a 1-hour period, the serum concentrations are similar to those obtained by intramuscular administration. Tobramycin is poorly absorbed from the gastrointestinal tract.

In patients with normal renal function, except neonates, Tobramycin administered every 8 hours does not accumulate in the serum. However, in those patients with reduced renal function and in neonates, the serum concentration of the antibiotic is usually higher and can be measured for longer periods of time than in normal adults. Dosage for such patients must, therefore, be adjusted accordingly (see DOSAGE AND ADMINISTRATION).

Following parenteral administration, little, if any, metabolic transformation occurs, and Tobramycin is eliminated almost exclusively by glomerular filtration. Renal clearance is similar to that of endogenous creatinine. Ultrafiltration studies demonstrate that practically no serum protein binding occurs. In patients with normal renal function, up to 84% of the dose is recoverable from the urine in 8 hours and up to 93% in 24 hours.

Peak urine concentrations ranging from 75 to 100 mcg/mL have been observed following the intramuscular injection of a single dose of 1 mg/kg. After several days of treatment, the amount of Tobramycin excreted in the urine approaches the daily dose administered. When renal function is impaired, excretion of Tobramycin is slowed, and accumulation of the drug may cause toxic blood levels.

The serum half-life in normal individuals is 2 hours. An inverse relationship exists between serum half-life and creatinine clearance, and the dosage schedule should be adjusted according to the degree of renal impairment (see DOSAGE AND ADMINISTRATION). In patients undergoing dialysis, 25% to 70% of the administered dose may be removed, depending on the duration and type of dialysis.

Tobramycin can be detected in tissues and body fluids after parenteral administration. Concentrations in bile and stools ordinarily have been low, which suggests minimum biliary excretion. Tobramycin has appeared in low concentration in the cerebrospinal fluid following parenteral administration, and concentrations are dependent on dose, rate of penetration, and degree of meningeal inflammation. It has also been found in sputum, peritoneal fluid, synovial fluid, and abscess fluids, and it crosses the placental membranes. Concentrations in the renal cortex are several times higher than the usual serum levels.

Probenecid does not affect the renal tubular transport of Tobramycin.

Microbiology— Tobramycin acts by inhibiting synthesis of protein in bacterial cells. In vitro tests demonstrate that Tobramycin is bactericidal.

Tobramycin has been shown to be active against most strains of the following organisms both in vitro and in clinical infections: (see INDICATIONS AND USAGE)

Gram-positive aerobes

Staphylococcus aureus

Gram-negative aerobes

Citrobacter sp

Enterobacter sp

Escherichia coli

Klebsiella sp

Morganella morganii

Pseudomonas aeruginosa

Proteus mirabilis

Proteus vulgaris

Providencia sp

Serratia sp

Aminoglycosides have a low order of activity against most gram-positive organisms, including Streptococcus pyogenes, Streptococcus pneumoniae, and enterococci.

Although most strains of enterococci demonstrate in vitro resistance, some strains in this group are susceptible. In vitro studies have shown that an aminoglycoside combined with an antibiotic that interferes with cell-wall synthesis affects some enterococcal strains synergistically. The combination of penicillin G and Tobramycin results in a synergistic bactericidal effect in vitro against certain strains of Enterococcus faecalis. However, this combination is not synergistic against other closely related organisms, e.g., Enterococcus faecium. Speciation of enterococci alone cannot be used to predict susceptibility. Susceptibility testing and tests for antibiotic synergism are emphasized.

Cross-resistance between aminoglycosides may occur.

Susceptibility Tests:

Diffusion Techniques: Quantitative methods that require measurement of zone diameters give the most precise estimate of the susceptibility of bacteria to antimicrobial agents. One such procedure is the National Committee for Clinical Laboratory Standards (NCCLS) approved procedure1. This method has been recommended for use with disks to test susceptibility to Tobramycin. Interpretation involves correlation of the diameters obtained in the disk test with the minimum inhibitory concentration (MIC) for Tobramycin.

Reports from the laboratory giving results of the standard single-disk susceptibility test with a 10-mcg Tobramycin disk should be interpreted according to the following criteria:

Zone diameter (mm)

Interpretation

≥ 15

(S) Susceptible

13-14

(I) Intermediate

≤ 12

(R) Resistant

A report of “Susceptible” indicates that the pathogen is likely to be inhibited by generally achievable blood levels. A report of “Intermediate” suggests that the organism would be susceptible if high dosage is used or if the infection is confined to tissues and fluids in which high antimicrobial levels are attained. A report of “Resistant” indicates that achievable concentrations are unlikely to be inhibitory, and other therapy should be selected.

Standardized procedures require the use of laboratory control organisms. The 10-mcg Tobramycin disk should give the following zone diameters:

Organism

Zone diameter (mm)

Escherichia coli ATCC 25922

18-26

Pseudomonas aeruginosa ATCC 27853

19-25

Staphylococcus aureus ATCC 25923

19-29

Dilution Techniques: Broth and agar dilution methods, such as those recommended by the NCCLS2, may be used to determine the minimum inhibitory concentration (MIC) of Tobramycin. MIC tests results should be interpreted according to the following criteria:

MIC (mcg/mL)

Interpretation

≤ 4

(S) Susceptible

8

(I) Intermediate

≥ 16

(R) Resistant

As with standard diffusion methods, dilution procedures require the use of laboratory control organisms. Standard Tobramycin powder should give the following MIC values:

Organism

MIC range (mcg/mL)

Enterococcus faecalis ATCC 29212

8.0-32.0

Escherichia coli ATCC 25922

0.25-1

Pseudomonas aeruginosa ATCC 27853

0.25-1

Staphylococcus aureus ATCC 29213

0.12-1

Indications and Usage for Tobramycin

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin and other antibacterial drugs, Tobramycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below:

Septicemia in the pediatric patient and adult caused by P aeruginosa, E coli, and Klebsiella sp

Lower respiratory tract infections caused by P aeruginosa, Klebsiella sp, Enterobacter sp, Serratia sp, E coli, and S aureus (penicillinase and non-penicillinase-producing strains)

Serious central-nervous-system infections (meningitis) caused by susceptible organisms

Intra-abdominal infections, including peritonitis, caused by E coli, Klebsiella sp, and Enterobacter sp

Skin, bone, and skin-structure infections caused by P aeruginosa, Proteus sp, E coli, Klebsiella sp, Enterobacter sp, and S aureus

Complicated and recurrent urinary tract infections caused by P aeruginosa, Proteus sp (indole-positive and indole-negative), E coli, Klebsiella sp, Enterobacter sp, Serratia sp, S aureus, Providencia sp, and Citrobacter sp

Aminoglycosides, including Tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use.

Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to Tobramycin. If susceptibility tests show that the causative organisms are resistant to Tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with Tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with Tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above.

Contraindications

A hypersensitivity to any aminoglycoside is a contraindication to the use of Tobramycin. A history of hypersensitivity or serious toxic reactions to aminoglycosides may also contraindicate the use of any other aminoglycoside because of the known cross-sensitivity of patients to drugs in this class.

Warnings

See WARNINGS box above.

Tobramycin Injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than nonasthmatic people.

Serious allergic reactions including anaphylaxis and dermatologic reactions including exfoliative dermatitis, toxic epidermal necrolysis, erythema multiforme, and Stevens-Johnson Syndrome have been reported rarely in patients on Tobramycin therapy. Although rare, fatalities have been reported (see CONTRAINDICATIONS).

If an allergic reaction occurs, the drug should be discontinued and appropriate therapy instituted.

Precautions

Serum and urine specimens for examination should be collected during therapy, as recommended in the WARNINGS box. Serum calcium, magnesium, and sodium should be monitored.

Peak and trough serum levels should be measured periodically during therapy. Prolonged concentrations above 12 mcg/mL should be avoided. Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation. Such accumulation, advanced age, and cumulative dosage may contribute to ototoxicity and nephrotoxicity. It is particularly important to monitor serum levels closely in patients with known renal impairment.

A useful guideline would be to perform serum level assays after 2 or 3 doses, so that the dosage could be adjusted if necessary, and also at 3-to 4-day intervals during therapy. In the event of changing renal function, more frequent serum levels should be obtained and the dosage or dosage interval adjusted according to the guidelines provided in the DOSAGE AND ADMINISTRATION section.

In order to measure the peak level, a serum sample should be drawn about 30 minutes following intravenous infusion or 1 hour after an intramuscular injection. Trough levels are measured by obtaining serum samples at 8 hours or just prior to the next dose of Tobramycin. These suggested time intervals are intended only as guidelines and may vary according to institutional practices. It is important, however, that there be consistency within the individual patient program unless computerized pharmacokinetic dosing programs are available in the institution. These serum-level assays may be especially useful for monitoring the treatment of severely ill patients with changing renal function or of those infected with less sensitive organisms or those receiving maximum dosage.

Neuromuscular blockade and respiratory paralysis have been reported in cats receiving very high doses of Tobramycin (40 mg/kg). The possibility of prolonged or secondary apnea should be considered if Tobramycin is administered to anesthetized patients who are also receiving neuromuscular blocking agents, such as succinylcholine, tubocurarine, or decamethonium, or to patients receiving massive transfusions of citrated blood. If neuromuscular blockade occurs, it may be reversed by the administration of calcium salts.

Cross-allergenicity among aminoglycosides has been demonstrated.

In patients with extensive burns or cystic fibrosis, altered pharmacokinetics may result in reduced serum concentrations of aminoglycosides. In such patients treated with Tobramycin, measurement of serum concentration is especially important as a basis for determination of appropriate dosage.

Elderly patients may have reduced renal function that may not be evident in the results of routine screening tests, such as BUN or serum creatinine. A creatinine clearance determination may be more useful. Monitoring of renal function during treatment with aminoglycosides is particularly important in such patients.

An increased incidence of nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins.

Aminoglycosides should be used with caution in patients with muscular disorders, such as myasthenia gravis or parkinsonism, since these drugs may aggravate muscle weakness because of their potential curare-like effect on neuromuscular function.

Aminoglycosides may be absorbed in significant quantities from body surfaces after local irrigation or application and may cause neurotoxicity and nephrotoxicity.

Aminoglycosides have not been approved for intraocular and/or subconjunctival use. Physicians are advised that macular necrosis has been reported following administration of aminoglycosides, including Tobramycin, by these routes.

See WARNINGS box regarding concurrent use of potent diuretics and concurrent and sequential use of other neurotoxic or nephrotoxic drugs.

The inactivation of Tobramycin and other aminoglycosides by β-lactam-type antibiotics (penicillins or cephalosporins) has been demonstrated in vitro and in patients with severe renal impairment. Such inactivation has not been found in patients with normal renal function who have been given the drugs by separate routes of administration.

Therapy with Tobramycin may result in overgrowth of nonsusceptible organisms. If overgrowth of nonsusceptible organisms occurs, appropriate therapy should be initiated.

Pregnancy Category D

Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Serious side effects to mother, fetus, or newborn have not been reported in the treatment of pregnant women with other aminoglycosides. If Tobramycin is used during pregnancy or if the patient becomes pregnant while taking Tobramycin, she should be apprised of the potential hazard to the fetus.

Pediatric Use

See INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION.

Geriatric Use

Elderly patients may be at a higher risk of developing nephrotoxicity and ototoxicity while receiving Tobramycin (see WARNINGS, PRECAUTIONS and OVERDOSAGE ). Other factors that may contribute to nephrotoxicity and ototoxicity are rising trough levels, excessive peak concentrations, dehydration, concomitant use of other neurotoxic or nephrotoxic drugs, and cumulative dose. Peak and trough serum levels should be measured periodically during therapy to assure adequate levels and to avoid potentially toxic levels (see WARNINGS and PRECAUTIONS).

Tobramycin is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Dose reduction is required for patients with impaired renal function (see DOSAGE AND ADMINISTRATION). Elderly patients may have reduced renal function that may not be evident in the results of routine screening tests, such as BUN or serum creatinine. A creatinine clearance determination may be more useful. Monitoring of renal function during treatment with aminoglycosides is particularly important in the elderly (see PRECAUTIONS).

Tobramycin 80 mg/8 mL vial contains 2.9 mg (0.13 mEq) of sodium.

General

Prescribing Tobramycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for Patients

Patients should be counseled that antibacterial drugs including Tobramycin should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Tobramycin is prescribed to treat a bacterial infection, the patient should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Tobramycin or other antibacterial drugs in the future.

Adverse Reactions

Neurotoxicity— Adverse effects on both the vestibular and auditory branches of the eighth nerve have been noted, especially in patients receiving high doses or prolonged therapy, in those given previous courses of therapy with an ototoxin, and in cases of dehydration. Symptoms include dizziness, vertigo, tinnitus, roaring in the ears, and hearing loss. Hearing loss is usually irreversible and is manifested initially by diminution of high-tone acuity. Tobramycin and gentamicin closely parallel each other in regard to ototoxic potential.

Nephrotoxicity— Renal function changes, as shown by rising BUN, NPN, and serum creatinine and by oliguria, cylindruria, and increased proteinuria, have been reported, especially in patients with a history of renal impairment who are treated for longer periods or with higher doses than those recommended. Adverse renal effects can occur in patients with initially normal renal function.

Clinical studies and studies in experimental animals have been conducted to compare the nephrotoxic potential of Tobramycin and gentamicin. In some of the clinical studies and in the animal studies, Tobramycin caused nephrotoxicity significantly less frequently than gentamicin. In some other clinical studies, no significant difference in the incidence of nephrotoxicity between Tobramycin and gentamicin was found.

Other reported adverse reactions possibly related to Tobramycin include anemia, granulocytopenia, and thrombocytopenia; and fever, rash, itching, urticaria, nausea, vomiting, diarrhea, headache, lethargy, pain at the injection site, mental confusion, and disorientation. Laboratory abnormalities possibly related to Tobramycin include increased serum transaminases (AST, ALT); increased serum LDH and bilirubin; decreased serum calcium, magnesium, sodium, and potassium; and leukopenia, leukocytosis, and eosinophilia.

Overdosage

Signs and Symptoms— The severity of the signs and symptoms following a Tobramycin overdose are dependent on the dose administered, the patient’s renal function, state of hydration, and age and whether or not other medications with similar toxicities are being administered concurrently. Toxicity may occur in patients treated more than 10 days, in adults given more than 5 mg/kg/day, pediatric patients given more than 7.5 mg/kg/day, or patients with reduced renal function whose dose has not been appropriately adjusted.

Nephrotoxicity following the parenteral administration of an aminoglycoside is most closely related to the area under the curve of the serum concentration versus time graph. Nephrotoxicity is more likely if trough blood concentrations fail to fall below 2 mcg/mL and is also proportional to the average blood concentration. Patients who are elderly, have abnormal renal function, are receiving other nephrotoxic drugs, or are volume depleted are at greater risk for developing acute tubular necrosis. Auditory and vestibular toxicity has been associated with aminoglycoside overdose; these toxicities occur in patients treated longer than 10 days, in patients with abnormal renal function, in dehydrated patients, or in patients receiving medications with additive auditory toxicities. These patients may not have signs or symptoms or may experience dizziness, tinnitus, vertigo, and a loss of high-tone acuity, as ototoxicity progresses. Ototoxicity signs and symptoms may not begin to occur until long after the drug has been discontinued.

Neuromuscular blockade or respiratory paralysis may occur following administration of many aminoglycosides. Neuromuscular blockade, respiratory failure, and prolonged respiratory paralysis may occur more commonly in patients with myasthenia gravis or Parkinson’s disease. Prolonged respiratory paralysis may also occur in patients receiving decamethonium, tubocurarine, or succinylcholine. If neuromuscular blockade occurs, it may be reversed by the administration of calcium salts but mechanical assistance may be necessary.

If Tobramycin were ingested, toxicity would be less likely because aminoglycosides are poorly absorbed from an intact gastrointestinal tract.

Treatment— In all cases of suspected overdosage, call your Regional Poison Control Center to obtain the most up-to-date information about the treatment of overdose. This recommendation is made because, in general, information regarding the treatment of overdose may change more rapidly than the package insert. In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.

The initial intervention in a Tobramycin overdose is to establish an airway and ensure oxygenation and ventilation. Resuscitative measures should be initiated promptly if respiratory paralysis occurs.

Patients that have received an overdose of Tobramycin and have normal renal function should be adequately hydrated to maintain a urine output of 3 to 5 mL/kg/hr. Fluid balance, creatinine clearance, and Tobramycin plasma levels should be carefully monitored until the serum Tobramycin level falls below 2 mcg/mL.

Patients in whom the elimination half-life is greater than 2 hours or whose renal function is abnormal may require more aggressive therapy. In such patients, hemodialysis may be beneficial.

Tobramycin Dosage and Administration

Tobramycin Injection, USP may be given intramuscularly or intravenously. Recommended dosages are the same for both routes. ADD-Vantage vials are not intravascular administration. The patient’s pretreatment body weight should be obtained for calculation of correct dosage. It is desirable to measure both peak and trough serum concentrations (see WARNINGS box and PRECAUTIONS).

Administration for Patients with Normal Renal Function— Adults with Serious Infections: 3 mg/kg/day in 3 equal doses every 8 hours (see Table 1).

Adults with Life-Threatening Infections: Up to 5 mg/kg/day may be administered in 3 or 4 equal doses (see Table 1). The dosage should be reduced to 3 mg/kg/day as soon as clinically indicated. To prevent increased toxicity due to excessive blood levels, dosage should not exceed 5 mg/kg/day unless serum levels are monitored (see WARNINGS box and PRECAUTIONS).

Table 1

DOSAGE SCHEDULE GUIDE FOR Tobramycin INJECTION

IN ADULTS WITH NORMAL RENAL FUNCTION

(Dosage at 8-Hour Intervals)

For

Patient

Weighing

Usual Dose for

Serious Infections

1 mg/kg q8h

Maximum Dose for Life-

Threatening Infections

(Reduce as soon as possible)

1.66 mg/kg q8h

kg

lb

(Total, 3 mg/kg/day)

(Total, 5 mg/kg/day)

mg/dose

mL/dose*

mg/dose

mL/dose*

q8h

q8h

120

264

120 mg

3 mL

200 mg

5 mL

115

253

115 mg

2.9 mL

191 mg

4.75 mL

110

242

110 mg

2.75 mL

183 mg

4.5 mL

105

231

105 mg

2.6 mL

175 mg

4.4 mL

100

220

100 mg

2.5 mL

166 mg

4.2 mL

95

209

95 mg

2.4 mL

158 mg

4 mL

90

198

90 mg

2.25 mL

150 mg

3.75 mL

85

187

85 mg

2.1 mL

141 mg

3.5 mL

80

176

80 mg

2 mL

133 mg

3.3 mL

75

165

75 mg

1.9 mL

125 mg

3.1 mL

70

154

70 mg

1.75 mL

116 mg

2.9 mL

65

143

65 mg

1.6 mL

108 mg

2.7 mL

60

132

60 mg

1.5 mL

100 mg

2.5 mL

55

121

55 mg

1.4 mL

91 mg

2.25 mL

50

110

50 mg

1.25 mL

83 mg

2.1 mL

45

99

45 mg

1.1 mL

75 mg

1.9 mL

40

88

40 mg

1 mL

66 mg

1.6 mL

* Applicable to all product forms except Tobramycin Injection, 10 mg/mL (Pediatric).

Pediatric Patients (Greater Than 1 Week of Age): 6 to 7.5 mg/kg/day in 3 or 4 equally divided doses (2 to 2.5 mg/kg every 8 hours or 1.5 to 1.89 mg/kg every 6 hours).

Premature or Full-Term Neonates 1 Week of Age or Less: Up to 4 mg/kg/day may be administered in 2 equal doses every 12 hours.

It is desirable to limit treatment to a short term. The usual duration of treatment is 7 to 10 days. A longer course of therapy may be necessary in difficult and complicated infections. In such cases, monitoring of renal, auditory, and vestibular functions is advised, because neurotoxicity is more likely to occur when treatment is extended longer than 10 days.

Dosage in Patients with Cystic Fibrosis— In patients with cystic fibrosis, altered pharmacokinetics may result in reduced serum concentration of aminoglycosides. Measurement of Tobramycin serum concentration during treatment is especially important as a basis for determining appropriate dose. In patients with severe cystic fibrosis, an initial dosing regimen of 10 mg/kg/day in 4 equally divided doses is recommended. This dosing regimen is suggested only as a guide. The serum levels of Tobramycin should be measured directly during treatment due to a wide interpatient variability.

Administration for Patients With Impaired Renal Function— Whenever possible, serum Tobramycin concentrations should be monitored during therapy.

Following a loading dose of 1 mg/kg, subsequent dosage in these patients must be adjusted, either with reduced doses administered at 8-hour intervals or with normal doses given at prolonged intervals. Both of these methods are suggested as guides to be used when serum levels of Tobramycin cannot be measured directly. They are based on either the creatinine clearance or the serum creatinine of the patient, because these values correlate with the half-life of Tobramycin. The dosage schedules derived from either method should be used in conjunction with careful clinical and laboratory observations of the patient and should be modified as necessary. Neither method should be used when dialysis is being performed.

Reduced dosage at 8-hour intervals: When the creatinine clearance rate is 70 mL or less per minute or when the serum creatinine value is known, the amount of the reduced dose can be determined by multiplying the normal dose from Table 1 by the percent of normal dose from the accompanying nomogram.

An alternate rough guide for determining reduced dosage at 8-hour intervals (for patients whose steady-state serum creatinine values are known) is to divide the normally recommended dose by the patient’s serum creatinine.

Normal dosage at prolonged intervals: If the creatinine clearance rate is not available and the patient’s condition is stable, a dosage frequency in hours for the dosage given in Table 1 can be determined by multiplying the patient’s serum creatinine by 6.

Dosage in Obese Patients— The appropriate dose may be calculated by using the patient’s estimated lean body weight plus 40% of the excess as the basic weight on which to figure mg/kg.

Intramuscular Administration— Tobramycin Injection may be administered by withdrawing the appropriate dose directly from a vial. Tobramycin sulfate in 0.9% Sodium Chloride is not intended for intramuscular administration.

Intravenous Administration— For intravenous administration, the usual volume of diluent (0.9% Sodium Chloride Injection or 5% Dextrose Injection) is 50 to 100 mL for adult doses. For pediatric patients, the volume of diluent should be proportionately less than for adults. The diluted solution usually should be infused over a period of 20 to 60 minutes. Infusion periods of less than 20 minutes are not recommended because peak serum levels may exceed 12 mcg/mL (see WARNINGS box).

Use of ADD-Vantage Vials— ADD-Vantage Tobramycin Injection vials are not intended for multiple use and should not be used with a syringe in the conventional way. These products are intended for use only with 50 mL or 100 mL ADD-Vantage Flexible Diluent Containers and in those instances in which the physician’s order specified 80 mg doses. Use within 24 hours after activation.

Tobramycin Injection should not be physically premixed with other drugs but should be administered separately according to the recommended dose and route.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

INSTRUCTIONS FOR USE

To Open Diluent Container:

Peel overwrap from the corner and remove container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

To Assemble Vial and Flexible Diluent Container:

(Use Aseptic Technique)

  1. Remove the protective covers from the top of the vial and the vial port on the diluent container as follows:

    a. To remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening (see FIGURE 1.), then pull straight up to remove the cap. (see FIGURE 2.) NOTE: Do not access vial with syringe.

    Fig. 1

    Fig. 2

    b. To remove the vial port cover, grasp the tab on the pull ring, pull up to break the three tie strings, then pull back to remove the cover. (see FIGURE 3.)

  2. Screw the vial into the vial port until it will go no further. THE VIAL MUST BE SCREWED IN TIGHTLY TO ASSURE A SEAL. This occurs approximately 1/2 turn (180°) after the first audible click. (see FIGURE 4.) The clicking sound does not assure a seal; the vial must be turned as far as it will go. NOTE: Once vial is seated, do not attempt to remove. (see FIGURE 4.)

  3. Recheck the vial to assure that it is tight by trying to turn it further in the direction of assembly.

  4. Label appropriately.

    Fig. 3

    Fig. 4

To Prepare Admixture:

  1. Squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial.

  2. With the other hand, push the drug vial down into the container telescoping the walls of the container. Grasp the inner cap of the vial through the walls of the container. (see FIGURE 5.)

  3. Pull the inner cap from the drug vial. (see FIGURE 6.) Verify that the rubber stopper has been pulled out, allowing the drug and diluent to mix.

  4. Mix container contents thoroughly and use within the specified time.

    Fig. 5

    Fig. 6

Preparation for Administration

(Use Aseptic Technique)

  1. Confirm the activation and admixture of vial contents.

  2. Check for leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired.

  3. Close flow control clamp of administration set.

  4. Remove cover from outlet port at bottom of container.

  5. Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated. NOTE: See full directions on administration set carton.

  6. Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings. Bend the loop outward to lock it in the upright position, then suspend container from hanger.

  7. Squeeze and release drip chamber to establish proper fluid level in chamber.

  8. Open flow control clamp and clear air from set. Close clamp.

  9. Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.

  10. Regulate rate of administration with flow control clamp.

WARNING: Do not use flexible container in series connections.

How is Tobramycin Supplied

Tobramycin Injection is supplied in single-dose ADD-Vantage Vials as follows:

List No.

Volume

Vials per Tray

Tobramycin content

3255

8 mL

25

80 mg

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Covered by one or more of the following U.S. patents: 4,614,515 and 4,614,267.

REFERENCES

  1. National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Disk Susceptibility Tests — Fourth Edition. Approved Standard NCCLS Document M2-A4, Vol. 10, No. 7, NCCLS, Villanova, PA, 1990.

  2. National Committee for Clinical Laboratory Standards, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically— Second Edition. Approved Standard NCCLS Document M7-A2, Vol. 10, No. 8, NCCLS, Villanova, PA, 1990.

©Hospira 2004

EN-0311

Printed in USA

HOSPIRA, INC., LAKE FOREST, IL 60045 USA


Tobramycin (Tobramycin)
PRODUCT INFO
Product Code 0409-3255 Dosage Form INJECTION, SOLUTION, CONCENTRATE
Route Of Administration INTRAVENOUS DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Tobramycin sulfate (Tobramycin) Active 10 MILLIGRAM  In 1 MILLILITER
Sodium Metabisulfite Inactive 1.5 MILLIGRAM  In 1 MILLILITER
Edetate Disodium Inactive 0.1 MILLIGRAM  In 1 MILLILITER
Sulfuric Acid Inactive  
Sodium Hydroxide Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0409-3255-03 25 VIAL In 1 TRAY contains a VIAL, PATENT DELIVERY SYSTEM
1 8 MILLILITER In 1 VIAL, PATENT DELIVERY SYSTEM This package is contained within the TRAY (0409-3255-03)

Revised: 05/2006





Where can I get more information about Tobramycin Injection Hospira Tobramycin Ophthalmic Solution ? We recommend to use www.Drugs.com

Typical mistypes for Tobramycin Injection Hospira Tobramycin Ophthalmic Solution
robramycin injection hospira tobramycin ophthalmic solution, fobramycin injection hospira tobramycin ophthalmic solution, gobramycin injection hospira tobramycin ophthalmic solution, yobramycin injection hospira tobramycin ophthalmic solution, 6obramycin injection hospira tobramycin ophthalmic solution, 5obramycin injection hospira tobramycin ophthalmic solution, tibramycin injection hospira tobramycin ophthalmic solution, tkbramycin injection hospira tobramycin ophthalmic solution, tlbramycin injection hospira tobramycin ophthalmic solution, tpbramycin injection hospira tobramycin ophthalmic solution, t0bramycin injection hospira tobramycin ophthalmic solution, t9bramycin injection hospira tobramycin ophthalmic solution, tovramycin injection hospira tobramycin ophthalmic solution, tonramycin injection hospira tobramycin ophthalmic solution, tohramycin injection hospira tobramycin ophthalmic solution, togramycin injection hospira tobramycin ophthalmic solution, tobeamycin injection hospira tobramycin ophthalmic solution, tobdamycin injection hospira tobramycin ophthalmic solution, tobfamycin injection hospira tobramycin ophthalmic solution, tobtamycin injection hospira tobramycin ophthalmic solution, tob5amycin injection hospira tobramycin ophthalmic solution, tob4amycin injection hospira tobramycin ophthalmic solution, tobrzmycin injection hospira tobramycin ophthalmic solution, tobrsmycin injection hospira tobramycin ophthalmic solution, tobrwmycin injection hospira tobramycin ophthalmic solution, tobrqmycin injection hospira tobramycin ophthalmic solution, tobranycin injection hospira tobramycin ophthalmic solution, tobrakycin injection hospira tobramycin ophthalmic solution, tobrajycin injection hospira tobramycin ophthalmic solution, tobramtcin injection hospira tobramycin ophthalmic solution, tobramgcin injection hospira tobramycin ophthalmic solution, tobramhcin injection hospira tobramycin ophthalmic solution, tobramucin injection hospira tobramycin ophthalmic solution, tobram7cin injection hospira tobramycin ophthalmic solution, tobram6cin injection hospira tobramycin ophthalmic solution, tobramyxin injection hospira tobramycin ophthalmic solution, tobramyvin injection hospira tobramycin ophthalmic solution, tobramyfin injection hospira tobramycin ophthalmic solution, tobramydin injection hospira tobramycin ophthalmic solution, tobramycun injection hospira tobramycin ophthalmic solution, tobramycjn injection hospira tobramycin ophthalmic solution, tobramyckn injection hospira tobramycin ophthalmic solution, tobramycon injection hospira tobramycin ophthalmic solution, tobramyc9n injection hospira tobramycin ophthalmic solution, tobramyc8n injection hospira tobramycin ophthalmic solution, tobramycib injection hospira tobramycin ophthalmic solution, tobramycim injection hospira tobramycin ophthalmic solution, tobramycij injection hospira tobramycin ophthalmic solution, tobramycih injection hospira tobramycin ophthalmic solution, tobramycin unjection hospira tobramycin ophthalmic solution, tobramycin jnjection hospira tobramycin ophthalmic solution, tobramycin knjection hospira tobramycin ophthalmic solution, tobramycin onjection hospira tobramycin ophthalmic solution, tobramycin 9njection hospira tobramycin ophthalmic solution, tobramycin 8njection hospira tobramycin ophthalmic solution, tobramycin ibjection hospira tobramycin ophthalmic solution, tobramycin imjection hospira tobramycin ophthalmic solution, tobramycin ijjection hospira tobramycin ophthalmic solution, tobramycin ihjection hospira tobramycin ophthalmic solution, tobramycin inhection hospira tobramycin ophthalmic solution, tobramycin innection hospira tobramycin ophthalmic solution, tobramycin inmection hospira tobramycin ophthalmic solution, tobramycin inkection hospira tobramycin ophthalmic solution, tobramycin iniection hospira tobramycin ophthalmic solution, tobramycin inuection hospira tobramycin ophthalmic solution, tobramycin injwction hospira tobramycin ophthalmic solution, tobramycin injsction hospira tobramycin ophthalmic solution, tobramycin injdction hospira tobramycin ophthalmic solution, tobramycin injrction hospira tobramycin ophthalmic solution, tobramycin inj4ction hospira tobramycin ophthalmic solution, tobramycin inj3ction hospira tobramycin ophthalmic solution, tobramycin injextion hospira tobramycin ophthalmic solution, tobramycin injevtion hospira tobramycin ophthalmic solution, tobramycin injeftion hospira tobramycin ophthalmic solution, tobramycin injedtion hospira tobramycin ophthalmic solution, tobramycin injecrion hospira tobramycin ophthalmic solution, tobramycin injecfion hospira tobramycin ophthalmic solution, tobramycin injecgion hospira tobramycin ophthalmic solution, tobramycin injecyion hospira tobramycin ophthalmic solution, tobramycin injec6ion hospira tobramycin ophthalmic solution, tobramycin injec5ion hospira tobramycin ophthalmic solution, tobramycin injectuon hospira tobramycin ophthalmic solution, tobramycin injectjon hospira tobramycin ophthalmic solution, tobramycin injectkon hospira tobramycin ophthalmic solution, tobramycin injectoon hospira tobramycin ophthalmic solution, tobramycin inject9on hospira tobramycin ophthalmic solution, tobramycin inject8on hospira tobramycin ophthalmic solution, tobramycin injectiin hospira tobramycin ophthalmic solution, tobramycin injectikn hospira tobramycin ophthalmic solution, tobramycin injectiln hospira tobramycin ophthalmic solution, tobramycin injectipn hospira tobramycin ophthalmic solution, tobramycin injecti0n hospira tobramycin ophthalmic solution, tobramycin injecti9n hospira tobramycin ophthalmic solution, tobramycin injectiob hospira tobramycin ophthalmic solution, tobramycin injectiom hospira tobramycin ophthalmic solution, tobramycin injectioj hospira tobramycin ophthalmic solution, tobramycin injectioh hospira tobramycin ophthalmic solution, tobramycin injection gospira tobramycin ophthalmic solution, tobramycin injection bospira tobramycin ophthalmic solution, tobramycin injection nospira tobramycin ophthalmic solution, tobramycin injection jospira tobramycin ophthalmic solution, tobramycin injection uospira tobramycin ophthalmic solution, tobramycin injection yospira tobramycin ophthalmic solution, tobramycin injection hispira tobramycin ophthalmic solution, tobramycin injection hkspira tobramycin ophthalmic solution, tobramycin injection hlspira tobramycin ophthalmic solution, tobramycin injection hpspira tobramycin ophthalmic solution, tobramycin injection h0spira tobramycin ophthalmic solution, tobramycin injection h9spira tobramycin ophthalmic solution, tobramycin injection hoapira tobramycin ophthalmic solution, tobramycin injection hozpira tobramycin ophthalmic solution, tobramycin injection hoxpira tobramycin ophthalmic solution, tobramycin injection hodpira tobramycin ophthalmic solution, tobramycin injection hoepira tobramycin ophthalmic solution, tobramycin injection howpira tobramycin ophthalmic solution, tobramycin injection hosoira tobramycin ophthalmic solution, tobramycin injection hoslira tobramycin ophthalmic solution, tobramycin injection hos-ira tobramycin ophthalmic solution, tobramycin injection hos0ira tobramycin ophthalmic solution, tobramycin injection hospura tobramycin ophthalmic solution, tobramycin injection hospjra tobramycin ophthalmic solution, tobramycin injection hospkra tobramycin ophthalmic solution, tobramycin injection hospora tobramycin ophthalmic solution, tobramycin injection hosp9ra tobramycin ophthalmic solution, tobramycin injection hosp8ra tobramycin ophthalmic solution, tobramycin injection hospiea tobramycin ophthalmic solution, tobramycin injection hospida tobramycin ophthalmic solution, tobramycin injection hospifa tobramycin ophthalmic solution, tobramycin injection hospita tobramycin ophthalmic solution, tobramycin injection hospi5a tobramycin ophthalmic solution, tobramycin injection hospi4a tobramycin ophthalmic solution, tobramycin injection hospirz tobramycin ophthalmic solution, tobramycin injection hospirs tobramycin ophthalmic solution, tobramycin injection hospirw tobramycin ophthalmic solution, tobramycin injection hospirq tobramycin ophthalmic solution, tobramycin injection hospira robramycin ophthalmic solution, tobramycin injection hospira fobramycin ophthalmic solution, tobramycin injection hospira gobramycin ophthalmic solution, tobramycin injection hospira yobramycin ophthalmic solution, tobramycin injection hospira 6obramycin ophthalmic solution, tobramycin injection hospira 5obramycin ophthalmic solution, tobramycin injection hospira tibramycin ophthalmic solution, tobramycin injection hospira tkbramycin ophthalmic solution, tobramycin injection hospira tlbramycin ophthalmic solution, tobramycin injection hospira tpbramycin ophthalmic solution, tobramycin injection hospira t0bramycin ophthalmic solution, tobramycin injection hospira t9bramycin ophthalmic solution, tobramycin injection hospira tovramycin ophthalmic solution, tobramycin injection hospira tonramycin ophthalmic solution, tobramycin injection hospira tohramycin ophthalmic solution, tobramycin injection hospira togramycin ophthalmic solution, tobramycin injection hospira tobeamycin ophthalmic solution, tobramycin injection hospira tobdamycin ophthalmic solution, tobramycin injection hospira tobfamycin ophthalmic solution, tobramycin injection hospira tobtamycin ophthalmic solution, tobramycin injection hospira tob5amycin ophthalmic solution, tobramycin injection hospira tob4amycin ophthalmic solution, tobramycin injection hospira tobrzmycin ophthalmic solution, tobramycin injection hospira tobrsmycin ophthalmic solution, tobramycin injection hospira tobrwmycin ophthalmic solution, tobramycin injection hospira tobrqmycin ophthalmic solution, tobramycin injection hospira tobranycin ophthalmic solution, tobramycin injection hospira tobrakycin ophthalmic solution, tobramycin injection hospira tobrajycin ophthalmic solution, tobramycin injection hospira tobramtcin ophthalmic solution, tobramycin injection hospira tobramgcin ophthalmic solution, tobramycin injection hospira tobramhcin ophthalmic solution, tobramycin injection hospira tobramucin ophthalmic solution, tobramycin injection hospira tobram7cin ophthalmic solution, tobramycin injection hospira tobram6cin ophthalmic solution, tobramycin injection hospira tobramyxin ophthalmic solution, tobramycin injection hospira tobramyvin ophthalmic solution, tobramycin injection hospira tobramyfin ophthalmic solution, tobramycin injection hospira tobramydin ophthalmic solution, tobramycin injection hospira tobramycun ophthalmic solution, tobramycin injection hospira tobramycjn ophthalmic solution, tobramycin injection hospira tobramyckn ophthalmic solution, tobramycin injection hospira tobramycon ophthalmic solution, tobramycin injection hospira tobramyc9n ophthalmic solution, tobramycin injection hospira tobramyc8n ophthalmic solution, tobramycin injection hospira tobramycib ophthalmic solution, tobramycin injection hospira tobramycim ophthalmic solution, tobramycin injection hospira tobramycij ophthalmic solution, tobramycin injection hospira tobramycih ophthalmic solution, tobramycin injection hospira tobramycin iphthalmic solution, tobramycin injection hospira tobramycin kphthalmic solution, tobramycin injection hospira tobramycin lphthalmic solution, tobramycin injection hospira tobramycin pphthalmic solution, tobramycin injection hospira tobramycin 0phthalmic solution, tobramycin injection hospira tobramycin 9phthalmic solution, tobramycin injection hospira tobramycin oohthalmic solution, tobramycin injection hospira tobramycin olhthalmic solution, tobramycin injection hospira tobramycin o-hthalmic solution, tobramycin injection hospira tobramycin o0hthalmic solution, tobramycin injection hospira tobramycin opgthalmic solution, tobramycin injection hospira tobramycin opbthalmic solution, tobramycin injection hospira tobramycin opnthalmic solution, tobramycin injection hospira tobramycin opjthalmic solution, tobramycin injection hospira tobramycin oputhalmic solution, tobramycin injection hospira tobramycin opythalmic solution, tobramycin injection hospira tobramycin ophrhalmic solution, tobramycin injection hospira tobramycin ophfhalmic solution, tobramycin injection hospira tobramycin ophghalmic solution, tobramycin injection hospira tobramycin ophyhalmic solution, tobramycin injection hospira tobramycin oph6halmic solution, tobramycin injection hospira tobramycin oph5halmic solution, tobramycin injection hospira tobramycin ophtgalmic solution, tobramycin injection hospira tobramycin ophtbalmic solution, tobramycin injection hospira tobramycin ophtnalmic solution, tobramycin injection hospira tobramycin ophtjalmic solution, tobramycin injection hospira tobramycin ophtualmic solution, tobramycin injection hospira tobramycin ophtyalmic solution, tobramycin injection hospira tobramycin ophthzlmic solution, tobramycin injection hospira tobramycin ophthslmic solution, tobramycin injection hospira tobramycin ophthwlmic solution, tobramycin injection hospira tobramycin ophthqlmic solution, tobramycin injection hospira tobramycin ophthakmic solution, tobramycin injection hospira tobramycin ophthapmic solution, tobramycin injection hospira tobramycin ophthaomic solution, tobramycin injection hospira tobramycin ophthalnic solution, tobramycin injection hospira tobramycin ophthalkic solution, tobramycin injection hospira tobramycin ophthaljic solution, tobramycin injection hospira tobramycin ophthalmuc solution, tobramycin injection hospira tobramycin ophthalmjc solution, tobramycin injection hospira tobramycin ophthalmkc solution, tobramycin injection hospira tobramycin ophthalmoc solution, tobramycin injection hospira tobramycin ophthalm9c solution, tobramycin injection hospira tobramycin ophthalm8c solution, tobramycin injection hospira tobramycin ophthalmix solution, tobramycin injection hospira tobramycin ophthalmiv solution, tobramycin injection hospira tobramycin ophthalmif solution, tobramycin injection hospira tobramycin ophthalmid solution, tobramycin injection hospira tobramycin ophthalmic aolution, tobramycin injection hospira tobramycin ophthalmic zolution, tobramycin injection hospira tobramycin ophthalmic xolution, tobramycin injection hospira tobramycin ophthalmic dolution, tobramycin injection hospira tobramycin ophthalmic eolution, tobramycin injection hospira tobramycin ophthalmic wolution, tobramycin injection hospira tobramycin ophthalmic silution, tobramycin injection hospira tobramycin ophthalmic sklution, tobramycin injection hospira tobramycin ophthalmic sllution, tobramycin injection hospira tobramycin ophthalmic splution, tobramycin injection hospira tobramycin ophthalmic s0lution, tobramycin injection hospira tobramycin ophthalmic s9lution, tobramycin injection hospira tobramycin ophthalmic sokution, tobramycin injection hospira tobramycin ophthalmic sopution, tobramycin injection hospira tobramycin ophthalmic sooution, tobramycin injection hospira tobramycin ophthalmic solytion, tobramycin injection hospira tobramycin ophthalmic solhtion, tobramycin injection hospira tobramycin ophthalmic soljtion, tobramycin injection hospira tobramycin ophthalmic solition, tobramycin injection hospira tobramycin ophthalmic sol8tion, tobramycin injection hospira tobramycin ophthalmic sol7tion, tobramycin injection hospira tobramycin ophthalmic solurion, tobramycin injection hospira tobramycin ophthalmic solufion, tobramycin injection hospira tobramycin ophthalmic solugion, tobramycin injection hospira tobramycin ophthalmic soluyion, tobramycin injection hospira tobramycin ophthalmic solu6ion, tobramycin injection hospira tobramycin ophthalmic solu5ion, tobramycin injection hospira tobramycin ophthalmic solutuon, tobramycin injection hospira tobramycin ophthalmic solutjon, tobramycin injection hospira tobramycin ophthalmic solutkon, tobramycin injection hospira tobramycin ophthalmic solutoon, tobramycin injection hospira tobramycin ophthalmic solut9on, tobramycin injection hospira tobramycin ophthalmic solut8on, tobramycin injection hospira tobramycin ophthalmic solutiin, tobramycin injection hospira tobramycin ophthalmic solutikn, tobramycin injection hospira tobramycin ophthalmic solutiln, tobramycin injection hospira tobramycin ophthalmic solutipn, tobramycin injection hospira tobramycin ophthalmic soluti0n, tobramycin injection hospira tobramycin ophthalmic soluti9n, tobramycin injection hospira tobramycin ophthalmic solutiob, tobramycin injection hospira tobramycin ophthalmic solutiom, tobramycin injection hospira tobramycin ophthalmic solutioj, tobramycin injection hospira tobramycin ophthalmic solutioh, obramycin injection hospira tobramycin ophthalmic solution, tbramycin injection hospira tobramycin ophthalmic solution, toramycin injection hospira tobramycin ophthalmic solution, tobamycin injection hospira tobramycin ophthalmic solution, tobrmycin injection hospira tobramycin ophthalmic solution, tobraycin injection hospira tobramycin ophthalmic solution, tobramcin injection hospira tobramycin ophthalmic solution, tobramyin injection hospira tobramycin ophthalmic solution, tobramycn injection hospira tobramycin ophthalmic solution, tobramyci injection hospira tobramycin ophthalmic solution, tobramycininjection hospira tobramycin ophthalmic solution, tobramycin njection hospira tobramycin ophthalmic solution, tobramycin ijection hospira tobramycin ophthalmic solution, tobramycin inection hospira tobramycin ophthalmic solution, tobramycin injction hospira tobramycin ophthalmic solution, tobramycin injetion hospira tobramycin ophthalmic solution, tobramycin injecion hospira tobramycin ophthalmic solution, tobramycin injecton hospira tobramycin ophthalmic solution, tobramycin injectin hospira tobramycin ophthalmic solution, tobramycin injectio hospira tobramycin ophthalmic solution, tobramycin injectionhospira tobramycin ophthalmic solution, tobramycin injection ospira tobramycin ophthalmic solution, tobramycin injection hspira tobramycin ophthalmic solution, tobramycin injection hopira tobramycin ophthalmic solution, tobramycin injection hosira tobramycin ophthalmic solution, tobramycin injection hospra tobramycin ophthalmic solution, tobramycin injection hospia tobramycin ophthalmic solution, tobramycin injection hospir tobramycin ophthalmic solution, tobramycin injection hospira tobramycin ophthalmic solution, tobramycin injection hospira tobramycin ophthalmic solution, tobramycin injection hospira obramycin ophthalmic solution, tobramycin injection hospira tbramycin ophthalmic solution, tobramycin injection hospira toramycin ophthalmic solution, tobramycin injection hospira tobamycin ophthalmic solution, tobramycin injection hospira tobrmycin ophthalmic solution, tobramycin injection hospira tobraycin ophthalmic solution, tobramycin injection hospira tobramcin ophthalmic solution, tobramycin injection hospira tobramyin ophthalmic solution, tobramycin injection hospira tobramycn ophthalmic solution, tobramycin injection hospira tobramyci ophthalmic solution, tobramycin injection hospira tobramycinophthalmic solution, tobramycin injection hospira tobramycin phthalmic solution, tobramycin injection hospira tobramycin ohthalmic solution, tobramycin injection hospira tobramycin opthalmic solution, tobramycin injection hospira tobramycin ophhalmic solution, tobramycin injection hospira tobramycin ophtalmic solution, tobramycin injection hospira tobramycin ophthlmic solution, tobramycin injection hospira tobramycin ophthamic solution, tobramycin injection hospira tobramycin ophthalic solution, tobramycin injection hospira tobramycin ophthalmc solution, tobramycin injection hospira tobramycin ophthalmi solution, tobramycin injection hospira tobramycin ophthalmicsolution, tobramycin injection hospira tobramycin ophthalmic olution, tobramycin injection hospira tobramycin ophthalmic slution, tobramycin injection hospira tobramycin ophthalmic soution, tobramycin injection hospira tobramycin ophthalmic soltion, tobramycin injection hospira tobramycin ophthalmic soluion, tobramycin injection hospira tobramycin ophthalmic soluton, tobramycin injection hospira tobramycin ophthalmic solutin, tobramycin injection hospira tobramycin ophthalmic solutio, otbramycin injection hospira tobramycin ophthalmic solution, tboramycin injection hospira tobramycin ophthalmic solution, torbamycin injection hospira tobramycin ophthalmic solution, tobarmycin injection hospira tobramycin ophthalmic solution, tobrmaycin injection hospira tobramycin ophthalmic solution, tobraymcin injection hospira tobramycin ophthalmic solution, tobramcyin injection hospira tobramycin ophthalmic solution, tobramyicn injection hospira tobramycin ophthalmic solution, tobramycni injection hospira tobramycin ophthalmic solution, tobramyci ninjection hospira tobramycin ophthalmic solution, tobramycini njection hospira tobramycin ophthalmic solution, tobramycin nijection hospira tobramycin ophthalmic solution, tobramycin ijnection hospira tobramycin ophthalmic solution, tobramycin inejction hospira tobramycin ophthalmic solution, tobramycin injcetion hospira tobramycin ophthalmic solution, tobramycin injetcion hospira tobramycin ophthalmic solution, tobramycin injeciton hospira tobramycin ophthalmic solution, tobramycin injectoin hospira tobramycin ophthalmic solution, tobramycin injectino hospira tobramycin ophthalmic solution, tobramycin injectio nhospira tobramycin ophthalmic solution, tobramycin injectionh ospira tobramycin ophthalmic solution, tobramycin injection ohspira tobramycin ophthalmic solution, tobramycin injection hsopira tobramycin ophthalmic solution, tobramycin injection hopsira tobramycin ophthalmic solution, tobramycin injection hosipra tobramycin ophthalmic solution, tobramycin injection hospria tobramycin ophthalmic solution, tobramycin injection hospiar tobramycin ophthalmic solution, tobramycin injection hospir a tobramycin ophthalmic solution, tobramycin injection hospira tobramycin ophthalmic solution, tobramycin injection hospira t obramycin ophthalmic solution, tobramycin injection hospira otbramycin ophthalmic solution, tobramycin injection hospira tboramycin ophthalmic solution, tobramycin injection hospira torbamycin ophthalmic solution, tobramycin injection hospira tobarmycin ophthalmic solution, tobramycin injection hospira tobrmaycin ophthalmic solution, tobramycin injection hospira tobraymcin ophthalmic solution, tobramycin injection hospira tobramcyin ophthalmic solution, tobramycin injection hospira tobramyicn ophthalmic solution, tobramycin injection hospira tobramycni ophthalmic solution, tobramycin injection hospira tobramyci nophthalmic solution, tobramycin injection hospira tobramycino phthalmic solution, tobramycin injection hospira tobramycin pohthalmic solution, tobramycin injection hospira tobramycin ohpthalmic solution, tobramycin injection hospira tobramycin opthhalmic solution, tobramycin injection hospira tobramycin ophhtalmic solution, tobramycin injection hospira tobramycin ophtahlmic solution, tobramycin injection hospira tobramycin ophthlamic solution, tobramycin injection hospira tobramycin ophthamlic solution, tobramycin injection hospira tobramycin ophthalimc solution, tobramycin injection hospira tobramycin ophthalmci solution, tobramycin injection hospira tobramycin ophthalmi csolution, tobramycin injection hospira tobramycin ophthalmics olution, tobramycin injection hospira tobramycin ophthalmic oslution, tobramycin injection hospira tobramycin ophthalmic sloution, tobramycin injection hospira tobramycin ophthalmic soultion, tobramycin injection hospira tobramycin ophthalmic soltuion, tobramycin injection hospira tobramycin ophthalmic soluiton, tobramycin injection hospira tobramycin ophthalmic solutoin, tobramycin injection hospira tobramycin ophthalmic solutino, ttobramycin injection hospira tobramycin ophthalmic solution, toobramycin injection hospira tobramycin ophthalmic solution, tobbramycin injection hospira tobramycin ophthalmic solution, tobrramycin injection hospira tobramycin ophthalmic solution, tobraamycin injection hospira tobramycin ophthalmic solution, tobrammycin injection hospira tobramycin ophthalmic solution, tobramyycin injection hospira tobramycin ophthalmic solution, tobramyccin injection hospira tobramycin ophthalmic solution, tobramyciin injection hospira tobramycin ophthalmic solution, tobramycinn injection hospira tobramycin ophthalmic solution, tobramycin injection hospira tobramycin ophthalmic solution, tobramycin iinjection hospira tobramycin ophthalmic solution, tobramycin innjection hospira tobramycin ophthalmic solution, tobramycin injjection hospira tobramycin ophthalmic solution, tobramycin injeection hospira tobramycin ophthalmic solution, tobramycin injecction hospira tobramycin ophthalmic solution, tobramycin injecttion hospira tobramycin ophthalmic solution, tobramycin injectiion hospira tobramycin ophthalmic solution, tobramycin injectioon hospira tobramycin ophthalmic solution, tobramycin injectionn hospira tobramycin ophthalmic solution, tobramycin injection hospira tobramycin ophthalmic solution, tobramycin injection hhospira tobramycin ophthalmic solution, tobramycin injection hoospira tobramycin ophthalmic solution, tobramycin injection hosspira tobramycin ophthalmic solution, tobramycin injection hosppira tobramycin ophthalmic solution, tobramycin injection hospiira tobramycin ophthalmic solution, tobramycin injection hospirra tobramycin ophthalmic solution, tobramycin injection hospiraa tobramycin ophthalmic solution, tobramycin injection hospira tobramycin ophthalmic solution, tobramycin injection hospira tobramycin ophthalmic solution, tobramycin injection hospira ttobramycin ophthalmic solution, tobramycin injection hospira toobramycin ophthalmic solution, tobramycin injection hospira tobbramycin ophthalmic solution, tobramycin injection hospira tobrramycin ophthalmic solution, tobramycin injection hospira tobraamycin ophthalmic solution, tobramycin injection hospira tobrammycin ophthalmic solution, tobramycin injection hospira tobramyycin ophthalmic solution, tobramycin injection hospira tobramyccin ophthalmic solution, tobramycin injection hospira tobramyciin ophthalmic solution, tobramycin injection hospira tobramycinn ophthalmic solution, tobramycin injection hospira tobramycin ophthalmic solution, tobramycin injection hospira tobramycin oophthalmic solution, tobramycin injection hospira tobramycin opphthalmic solution, tobramycin injection hospira tobramycin ophhthalmic solution, tobramycin injection hospira tobramycin ophtthalmic solution, tobramycin injection hospira tobramycin ophthhalmic solution, tobramycin injection hospira tobramycin ophthaalmic solution, tobramycin injection hospira tobramycin ophthallmic solution, tobramycin injection hospira tobramycin ophthalmmic solution, tobramycin injection hospira tobramycin ophthalmiic solution, tobramycin injection hospira tobramycin ophthalmicc solution, tobramycin injection hospira tobramycin ophthalmic solution, tobramycin injection hospira tobramycin ophthalmic ssolution, tobramycin injection hospira tobramycin ophthalmic soolution, tobramycin injection hospira tobramycin ophthalmic sollution, tobramycin injection hospira tobramycin ophthalmic soluution, tobramycin injection hospira tobramycin ophthalmic soluttion, tobramycin injection hospira tobramycin ophthalmic solutiion, tobramycin injection hospira tobramycin ophthalmic solutioon, tobramycin injection hospira tobramycin ophthalmic solutionn, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved